Document Detail


A randomised, controlled trial of bosentan in severe COPD.
MedLine Citation:
PMID:  18448495     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pulmonary hypertension during exercise is common in severe chronic obstructive pulmonary disease (COPD). It was hypothesised that the use of the endothelin-receptor antagonist bosentan can improve cardiopulmonary haemodynamics during exercise, thus increasing exercise tolerance in patients with severe COPD. In the present double-blind, placebo-controlled study, 30 patients with severe or very severe COPD were randomly assigned in a 2:1 ratio to receive either bosentan or placebo for 12 weeks. The primary end-point was change in the 6-min walking distance. Secondary end-points included changes in health-related quality of life, lung function, cardiac haemodynamics, maximal oxygen uptake and pulmonary perfusion patterns. Compared with placebo, patients treated with bosentan during 12 weeks showed no significant improvement in exercise capacity as measured by the 6-min walking distance (mean+/-SD 331+/-123 versus 329+/-94 m). There was no change in lung function, pulmonary arterial pressure, maximal oxygen uptake or regional pulmonary perfusion pattern. In contrast, arterial oxygen pressure dropped, the alveolar-arterial gradient increased and quality of life deteriorated significantly in patients assigned bosentan. The oral administration of the endothelin receptor antagonist bosentan not only failed to improve exercise capacity but also deteriorated hypoxaemia and functional status in severe chronic obstructive pulmonary disease patients without severe pulmonary hypertension at rest.
Authors:
D Stolz; H Rasch; A Linka; M Di Valentino; A Meyer; M Brutsche; M Tamm
Related Documents :
10864615 - Isolated finger flexion: a novel form of focal neuromyotonia.
7875145 - Pulmonary function of a firemen-diver population: a longitudinal study.
2382905 - Effect of percutaneous transcatheter embolization on pulmonary function, right-to-left ...
3576055 - Pulmonary vascular reactivity and hemorheology in patients with chronic cor pulmonale: ...
3945675 - Trager psychophysical integration. a method to improve chest mobility of patients with ...
7278355 - Lung function in tetralogy of fallot after intracardiac repair.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-04-30
Journal Detail:
Title:  The European respiratory journal     Volume:  32     ISSN:  1399-3003     ISO Abbreviation:  Eur. Respir. J.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-09-01     Completed Date:  2009-01-13     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  8803460     Medline TA:  Eur Respir J     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  619-28     Citation Subset:  IM    
Affiliation:
Clinic of Pulmonary Medicine and Respiratory Cell Research, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland. dstolz@uhbs.ch
Data Bank Information
Bank Name/Acc. No.:
ISRCTN/ISRCTN98252311
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anoxia
Double-Blind Method
Exercise Tolerance / drug effects
Female
Humans
Hypertension, Pulmonary / complications*,  drug therapy*
Male
Middle Aged
Pulmonary Disease, Chronic Obstructive / complications*,  pathology
Quality of Life
Sulfonamides / adverse effects*
Vasodilator Agents / adverse effects*
Chemical
Reg. No./Substance:
0/Sulfonamides; 0/Vasodilator Agents; Q326023R30/bosentan
Comments/Corrections
Comment In:
Eur Respir J. 2009 Feb;33(2):449; author reply 452-3   [PMID:  19181925 ]
Eur Respir J. 2008 Sep;32(3):541-2   [PMID:  18757693 ]
Eur Respir J. 2009 Feb;33(2):449-50; author reply 452-3   [PMID:  19181924 ]
Eur Respir J. 2009 Feb;33(2):450-2; author reply 452-3   [PMID:  19181926 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The association between HIV and antituberculosis drug resistance.
Next Document:  Determinants of hospital costs in community-acquired pneumonia.